A ban on a plastic chemical in IV bags passed the House 202-0. One Senate vote would send it to Shapiro
House Bill 2614 would phase DEHP out of IV bags by 2030 and IV tubing by 2035. It is on the Senate's Nov. 17 calendar, unamended, 38 days after it passed the House.
A bill to take a plastic-softening chemical out of IV bags and tubing could become law with one Senate vote. House Bill 2614 is on the Senate's Nov. 17 calendar for third consideration. The Senate hasn't amended it, so if senators pass it as printed it goes straight to Gov. Josh Shapiro.
Why it matters: DEHP is the most common plasticizer in medical devices, the bill says, and it is used in the bags and lines that deliver fluids and drugs to hospital patients. The bill's findings cite the U.S. Environmental Protection Agency's classification of DEHP as a probable human carcinogen and research linking it to reproductive harm.
A fast track
The bill moved quickly for this session. From its official history:
- June 8, 2026: introduced by Rep. Bridget Kosierowski (D-Lackawanna), a nurse, with 23 co-sponsors.
- June 17: amended and reported by the House Health Committee.
- Oct. 5: passed the House 202-0.
- Oct. 19: reported without changes by the Senate Institutional Sustainability and Innovation Committee, chaired by Sen. Frank Farry (R-Bucks), at an off-the-floor meeting.
- Oct. 20: second consideration in the Senate, then re-referred to and reported from Appropriations.
That's 38 days from House passage to Thursday. Many bills on this calendar have waited far longer; our REAL ID article covers one that passed the House in April 2025.
What it would require
From the bill text, Printer's No. 3633:
- IV bags: starting Jan. 1, 2030, no one could make, sell or distribute IV solution containers with intentionally added DEHP.
- IV tubing: the same ban starts Jan. 1, 2035.
- No swaps: manufacturers couldn't replace DEHP with another ortho-phthalate, a family of 11 related chemicals the bill lists, in new or revised devices.
- Trace amounts: unintentionally added DEHP would be capped at 0.1% by weight.
- Exemptions: blood collection and storage bags, and apheresis and cell therapy kits.
- Extension: a maker could have until Jan. 1, 2032, for IV bags if it is waiting on FDA approval or lacks equipment, as long as it told Pennsylvania customers by Dec. 31, 2026, that it had begun developing a DEHP-free bag, and posts notice by Jan. 1, 2028, that it will miss the deadline. The House committee moved that first notice date from July 1, 2026, which had already passed by then.
The act would take effect 90 days after signing.
What Kosierowski says
Her office said the legislation "would phase out DEHP" and cited research linking the chemical to breast, liver, lung and testicular cancer, according to her news page. The bill's findings also cite research that DEHP leaching from devices may make some breast cancer cells resistant to drugs.
We found no public statement from medical device makers or hospital groups on the Pennsylvania bill.
Advertisement
What happens next
The Senate convenes at 1 p.m. Nov. 17 and meets again Nov. 18, its last scheduled voting days. A bill on the calendar isn't guaranteed a vote. If HB 2614 isn't passed by Nov. 30, it dies and would have to be reintroduced in January.
Our calendar article lists the other bills that could still reach the governor. We covered another chemical issue the legislature didn't finish, PFAS in waterways, earlier this fall.